Too high or too low? ESMO’s clinical benefit scale fuels debate over approval thresholds
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]